{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:54:18Z","timestamp":1777658058296,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Research"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.brainres.2005.04.069","type":"journal-article","created":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T13:39:29Z","timestamp":1117633169000},"page":"177-184","source":"Crossref","is-referenced-by-count":20,"title":["DPP IV inhibitor blocks mescaline-induced scratching and amphetamine-induced hyperactivity in mice"],"prefix":"10.1016","volume":"1048","author":[{"given":"Susan L.","family":"Lautar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilo","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara S.","family":"Slusher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystyna M.","family":"Wozniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajit G.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Waldon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Ferraris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergei","family":"Belyakov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brainres.2005.04.069_bib1","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2337\/diacare.25.5.869","article-title":"Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes","volume":"25","author":"Ahren","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.brainres.2005.04.069_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0028-3908(96)00161-X","article-title":"The pharmacology of the novel and selective sigma ligand, PD 144418","volume":"36","author":"Akunne","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.brainres.2005.04.069_bib3","unstructured":"S. Belyakov, G. Hamilton, D.S. Hurst, V.J. Kalish, W. Li, E. Wang, D. Wilkinson, Y. Wu, X. Xu, Patent WO 03\/057666 (2003)."},{"key":"10.1016\/j.brainres.2005.04.069_bib4","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/0003-2697(92)90478-P","article-title":"Assay of apical membrane enzymes based on fluorogenic substrates","volume":"200","author":"Blackmon","year":"1992","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.brainres.2005.04.069_bib5","first-page":"212","article-title":"Action de la cafeine sur a la motile spontanee de la souris","volume":"158","author":"Bossier","year":"1965","journal-title":"Arch. Int. Pharmacodyn."},{"key":"10.1016\/j.brainres.2005.04.069_bib6","first-page":"1159","article-title":"DuP 734 [1-(cyclopropylmethyl)-4-(2\u2032(4\u02ba-fluorophenyl)-2\u2032-oxoethyl)piperidine HBr], a potential antipsychotic agent: preclinical behavioral effects","volume":"263","author":"Cook","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.brainres.2005.04.069_bib7","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0014-2999(81)90089-3","article-title":"Characterisation of the mechanisms by which purported dopamine agonists reduce spontaneous locomotor activity of mice","volume":"73","author":"Costall","year":"1981","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.brainres.2005.04.069_bib8","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0091-3057(90)90298-V","article-title":"Actions of ORG 5222 as a novel psychotropic agent","volume":"35","author":"Costall","year":"1990","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.brainres.2005.04.069_bib9","first-page":"17A","article-title":"A study of the antimescaline property of a series of CNS active agents in mice","volume":"122","author":"Deegan","year":"1958","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.brainres.2005.04.069_bib10","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nbt0797-673","article-title":"Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV","volume":"15","author":"Drucker","year":"1997","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.brainres.2005.04.069_bib11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0736-5748(90)90008-P","article-title":"Localization of dipeptidylpeptidase IV and alkaline phosphatase in developing spinal cord meninges and peripheral nerve coverings of the rat","volume":"8","author":"Haninec","year":"1990","journal-title":"Int. J. Dev. Neurosci."},{"key":"10.1016\/j.brainres.2005.04.069_bib12","first-page":"2884","article-title":"In vivo and in vitro degradation of glucagon-like peptide-2 in humans","volume":"85","author":"Hartmann","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.brainres.2005.04.069_bib13","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0091-3057(03)00154-0","article-title":"Behavioral effects of neuropeptide Y in F344 rat substrains with a reduced dipeptidyl-peptidase IV activity","volume":"75","author":"Karl","year":"2003","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.brainres.2005.04.069_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0149-7634(01)00066-5","article-title":"The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y","volume":"26","author":"Kask","year":"2002","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.brainres.2005.04.069_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1567-133X(01)00003-5","article-title":"Reduced neuropeptide Y mRNA levels in the frontal cortex of people with schizophrenia and bipolar disorder","volume":"1","author":"Kuromitsu","year":"2001","journal-title":"Gene Expr. Patterns"},{"key":"10.1016\/j.brainres.2005.04.069_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1996.tb10612.x","article-title":"Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs","volume":"93","author":"Maes","year":"1996","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.brainres.2005.04.069_bib17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0893-133X(00)00168-8","article-title":"Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy","volume":"24","author":"Maes","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.brainres.2005.04.069_bib18","first-page":"415","article-title":"Therapeutic perspectives for type 2 diabetes mellitus: molecular and clinical insights","volume":"27","author":"Mauvais-Jarvis","year":"2001","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.brainres.2005.04.069_bib19","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0196-9781(98)00071-0","article-title":"Processing of neuropeptide Y and somatostatin in human cerebrospinal fluid as monitored by radioimmunoassay and mass spectrometry","volume":"19","author":"Nilsson","year":"1998","journal-title":"Peptides"},{"key":"10.1016\/j.brainres.2005.04.069_bib20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/syn.10216","article-title":"Changes in NPY-mediated modulation of hippocampal [3H]D-aspartate outflow in the kindling model of epilepsy","volume":"49","author":"Rodi","year":"2003","journal-title":"Synapse"},{"key":"10.1016\/j.brainres.2005.04.069_bib21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0006-2952(03)00391-5","article-title":"Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptydal peptidase IV: an in vitro and in vivo study","volume":"66","author":"Sakurada","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.brainres.2005.04.069_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1139\/o95-013","article-title":"Detection of dipeptidyl peptidase IV in glioma C6 and neuroblastoma SK-N-SH cell lines","volume":"73","author":"Sedo","year":"1995","journal-title":"Biochem. Cell. Biol."},{"key":"10.1016\/j.brainres.2005.04.069_bib23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/(SICI)1098-2396(20000315)35:4<292::AID-SYN7>3.0.CO;2-3","article-title":"Differential effects of haloperidol on phencyclidine-induced reduction in substance P contents in rat brain regions","volume":"35","author":"Shirayama","year":"2000","journal-title":"Synapse"},{"key":"10.1016\/j.brainres.2005.04.069_bib24","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0024-3205(00)00689-5","article-title":"Analgesic effects of endomorphin-1 and endomorphin-2 in the formalin test in mice","volume":"67","author":"Soignier","year":"2000","journal-title":"Life Sci."},{"issue":"9","key":"10.1016\/j.brainres.2005.04.069_bib25","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0196-9781(02)00100-6","article-title":"In vitro quantitative study of the degradation of endomorphins","volume":"23","author":"Tomboly","year":"2002","journal-title":"Peptides"},{"key":"10.1016\/j.brainres.2005.04.069_bib26","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0196-9781(02)00100-6","article-title":"In vitro quantitative study of the degradation of endomorphins","volume":"23","author":"Tomboly","year":"2002","journal-title":"Peptides"},{"key":"10.1016\/j.brainres.2005.04.069_bib27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0166-4328(03)00212-2","article-title":"Increased amphetamine-induced locomotion during inactivation of the basolateral amygdala","volume":"149","author":"Woods","year":"2004","journal-title":"Behav. Brain Res."}],"container-title":["Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000689930500675X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000689930500675X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T23:03:09Z","timestamp":1550876589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000689930500675X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":27,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S000689930500675X"],"URL":"https:\/\/doi.org\/10.1016\/j.brainres.2005.04.069","relation":{},"ISSN":["0006-8993"],"issn-type":[{"value":"0006-8993","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}